ArticleBreast cancer (Tokyo, Japan)2021
The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Article in Breast cancer (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Local graph estimation with pathwise false discovery control.Nature communications · 2026Article
- Lobular breast cancer and prognosis: what should we tell patients?Frontiers in oncology · 2026Review
- Survival analysis of metachronous bilateral ectopic breast cancer utilizing the SEER database and the pioneering construction of a nomogram model.European journal of medical research · 2025Article
- Retrospective insights: clinical characteristics and survival in 403 ILC cases from China.BMC cancer · 2025Article
- Prognostic Importance of PTEN and P53 in Aggressive Luminal A Subtype Breast Cancers.European journal of breast health · 2025Article
- Novel nomograms for predicting overall survival and cancer-specific survival in invasive lobular carcinoma of the breast.Discover oncology · 2025Article
- An explainable AI-driven deep neural network for accurate breast cancer detection from histopathological and ultrasound images.Scientific reports · 2025Article
- Bayesian Spatial Analysis of the Incidence Rate of Patients with Breast Cancer in Southern Iran.Iranian journal of medical sciences · 2025Article
- Comparison of Invasive Ductolobular Carcinoma and Lobular Carcinoma: An Observational Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Psychological Considerations Associated with Lobular Breast Cancer.Current psychiatry reports · 2025Review
- Review
- Article
- Comprehensive characterization of invasive mammary carcinoma with lobular features: integrating morphology and E-cadherin immunohistochemistry patterns.Breast cancer (Tokyo, Japan) · 2025Article
- Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Micro-RNAs in breast cancer progression and metastasis: A chromatin and metabolic perspective.Heliyon · 2024Review
- Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.Breast cancer research : BCR · 2024Article
- Comparison of long-term outcome between clinically high risk lobular versus ductal breast cancer: a propensity score matched study.EClinicalMedicine · 2024Article
- Genomic disparity impacts variant classification of cancer susceptibility genes in Turkish breast cancer patients.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the prognosis of females with invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and mixed invasive ductal and lobular carcinoma (IDLC) according to hormone receptor (HR) and HER2 status.
methodsData of 171,881 patients from the SEER database were analyzed. Propensity score matching was used to balance the covariates. Breast cancer-specific survival (BCSS) and overall survival (OS) of IDC, ILC, and IDLC were investigated.
resultsPatients with ILC were older, had lower tumor grade, higher tumor stage, larger tumor size, more nodal metastasis, higher estrogen receptor(+), lower HER2(-), and less likely to receive partial mastectomy and chemotherapy compared with IDC and IDLC. ILC and IDLC showed better prognosis than IDC after matching by Kaplan-Meier curves. Multivariate Cox regression showed better OS of ILC and IDLC compared with IDC with hazard ratio and a 95% confidence interval of 0.84 (0.77-0.90) and 0.91 (0.83-1.00), respectively. For HR(+)HER2(-) subgroup, ILC showed better OS than IDC; IDC showed worse BCSS and OS than IDLC. For HR(+)HER2(+); ILC showed better OS compared with IDLC; there were no survival differences of IDC, ILC, and IDLC for HER2(+). For HR(-)HER2(-), ILC and IDC showed better BCSS and OS compared with IDLC by multivariate analysis.
conclusionsThe prognoses of female patients with IDC, ILC or IDLC were associated with the molecular subtypes of breast carcinoma. Management decisions should be based on pathological types and molecular subtypes.
Indexed as
Identifiers
32812198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.